Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04422899 · ClinicalTrials.gov registry record · Phase 1
Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration
A Phase 1 study, sponsored by AiViva BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04422899 is a Phase 1 study that has completed, run by AiViva BioPharma. The registered enrollment target is 3 participants.
The verdict
NCT04422899, a Phase 1 study, has completed, sponsored by AiViva BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
To determine safety, pharmacokinetics, and duration of effect of intravitreally administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration
Interventions
- DRUG AIV007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2022-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04422899
The ClinicalTrials.gov registry entry for NCT04422899 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AiViva BioPharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AIV007 is the first listed.
NCT04422899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04422899 about?
NCT04422899 is a clinical study titled "Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration". To determine safety, pharmacokinetics, and duration of effect of intravitreally administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration
What is the current status of trial NCT04422899?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-08-28. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT04422899?
The interventions under investigation include: AIV007 (DRUG).
Who is sponsoring clinical trial NCT04422899?
This trial is sponsored by AiViva BioPharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.